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ABSTRACT Escort aptamers are DNA or RNA sequences with high affinity to certain cell-surface proteins, which 
can be used for  targeted delivery of various agents into  cells of a definite type. The peculiarities of the selection 
of escort aptamers are discussed in this review. The methods used in selection of escort aptamers via the SELEX 
technique are considered, including selection against isolated cell-surface proteins, cell fragments, living eukary-
otic cells, and bacteria. Particular attention is given to the design and chemical modification of escort aptamers. 
The different fields of application of escort aptamers are described, including the targeted delivery of siRNAs, 
nanoparticles, toxins, and photoagents, as well as the identification of specific cell markers and the detection or 
isolation of cells of a definite type. The potential for the application of escort aptamers in the development of new 
therapeutic agents and diagnostic systems is also discussed.
KEYWORDS SELEX method; NA aptamers; escort aptamers; specific cell binding; addressed cell delivery; detec-
tion of cells.
ABBREVIATIONS dsDNA – double-stranded DNA; ssDNA – single-stranded DNA; siRNA – small interfering RNA; 
PSMA – prostate-specific membrane antigen; IC50 – therapeutical concentration required to suppress the growth 
of 50% cells; Kd – apparent constant of dissociation of the aptamer–target complex; LNA – locked nucleic acids; 
SELEX – Systematic Evolution of Ligands by EXponential Enrichment.
INTRODUCTION
Aptamers (Latin aptus – suitable) are single-stranded 
DnA and rnA molecules that are capable of  specific 
recognition of definite types of compounds, thanks to 
their unique spatial structure. In the 1990s,  methods 
for in vitro selection, enabling one to obtain nucleic ac-
ids with predetermined properties, were described by 
three independent research groups. A. ellington and 
J. Szostak [1] obtained an rnA molecule that was ca-
pable of specifically binding to an organic dye. c. tuerk 
and L. Gold described the selection of rnA molecules 
that were capable of binding to  phage 4 DnA polymer-
ase and called the developed method  SeLeX (System-
atic evolution of Ligands by exponential enrichment) 
[2]. D. robertson and G. Joyce used in vitro selection to 
convert  a group I ribozyme from a ribonuclease into 
a deoxyribonuclease [3]. throughout the subsequent 
two decades, this field has  developed rapidly;  meth-
ods for the selection of aptamers and  approaches to 
their design have been further refined. A large number 
of aptamers capable of binding to various targets with   
high specificity have already been obtained (see re-
views [4–7]). Aptamers find broad application across 
a wide range of research fields, thanks to their unique 
properties (namely their high affinity and selectivity 
in binding to a target molecule). In particular, aptam-
ers can be used to obtain highly efficient and specific 
inhibitors of target proteins that can be applied in the 
design of new drugs. A number of aptamers are cur-
rently in different stages of clinical trials [8]. Macugen 
(Eyetech Pharmaceuticals and Pfizer), which is based on 
aptamer binding a human vascular endothelial growth 
factor (VeGF), has been certified as an efficient drug 
for the treatment of age-related macular degeneration 
[9, 10].
One of the most interesting and promising aspects 
in the field is designing aptamers that are capable of   
specific recognition of cells of a definite type through 
binding with certain dominants on their surface. In the 
review by B. Hicke et al. [11], these compounds were 
referred to as escort aptamers. the use of escort aptam-
ers as an addressing fragment opens wide possibilities 
for the targeted delivery of agents of different nature 
to  cells of  definite types. today, a large number of reVIeWS
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escort aptamers directed toward various target cells 
have been obtained, and a wide range of applications 
for these aptamers for specific action on cells, diagnos-
tics, and cell isolation have been described. the present 
review is devoted to the selection, design, and different 
aspects in the use of escort aptamers.
OBTAINMENT OF APTAMERS BY in vitro SELECTION
The general principle of the SELEX method
DnA and rnA aptamers are obtained via in vitro se-
lection from combinatorial libraries of nucleic acid 
molecules. A conventional library is a set of oligonu-
cleotides with the randomized region consisting of 
20–60 nucleotides flanked with the constant regions 
that are required for binding to primers and the Pcr 
amplification of DnA.  currently, libraries containing 
both ssDnA and rnA molecules are widely used for 
the selection of aptamers. rnA aptamers are capable of 
forming a greater variety of spatial structures as com-
pared with DnA aptamers, as a result of the presence 
of 2'-OH groups. However, rnA aptamers are more 
sensitive to the action of cell nucleases and require the 
introduction of additional protective groups [12].
the ssDnA libraries are obtained via the conven-
tional methods for the chemical synthesis of oligodeox-
yribonucleotides using a mixture of all four monomers 
when synthesizing a randomized fragment. In order to 
obtain an rnA library, the chemical synthesis of an 
ssDnA library containing the promoter sequence for 
t7 rnA polymerase at its 5'-terminal region is first 
performed. the ssDnA matrix is then used to obtain a 
dsDnA, which is subsequently applied for the synthesis 
of rnA via in vitro transcription. the general scheme 
of the SeLeX method for DnA libraries comprises the 
following stages: incubation of a library with a tar-
get,  separation of oligonucleotide–target complexes 
from the unbound oligonucleotides, disruption of the 
oligonucleotide–target complexes, and  amplification 
of the bound molecules (Fig. 1A). For the selection of 
rnA aptamers, SeLeX also comprises the following 
additional stages: production of the rnA library on the 
DnA matrix, reverse transcription of the bound rnA 
molecules to produce DnA, and DnA amplification 
(Fig. 1B).
During the selection process, the library is enriched 
in sequences possessing  increased affinity to the tar-
get. Five to fifteen rounds of selection are typically per-
formed to obtain aptamers, depending on the values of 
the dissociation constant of the aptamer–target com-
plex. After the dissociation constant ceases to decrease 
(i.e., the affinity of the library to the target stops rising), 
the enriched library is cloned, and the sequences of the 
individual aptamers are determined. the homology be-
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tween the individual aptamers is then analyzed. On the 
basis of the results obtained, the aptamers are classified 
into several groups; their capability to interact with the 
target is assessed. the sequences with the maximum 
affinity to the target are selected for  further studies. 
the secondary structure of aptamers is studied by  an-
alyzing their conserved motifs, by computer simula-
tion, and chemical and enzymatic probing. the minimal 
size of an aptamer required for specific recognition of a 
target is determined at the next stage. For this purpose, 
a series of truncated variants of the aptamer is synthe-
sized and the ability of these aptamers to bind to the 
target is determined.
Aptamers are usually characterized by  high affinity 
to their targets. the characteristic values of the dissoci-
ation constant (Kd) for protein targets lie in the nanomo-
lar and subnanomolar ranges (1 × 10–10–1 × 10–7 М). In 
terms of their affinity and specificity, aptamers are 
similar to monoclonal antibodies; however, aptamers 
have a number of  distinct characterisitcs (Table 1). 
Among these characteristics, the possibilities to pro-
duce an aptamer via chemical synthesis and  to modify 
them chemically  are the ones most worthy of note.
Chemical modifications of aptamers
the introduction of different modifications into escort 
aptamers enables one to considerably increase their sta-
bility in biological media, as well as their functionality. 
the introduction of different substituents at the 2' po-
sition of ribose (Fig. 2) (the most common modification 
used to increase an aptamer’s stability) helps to prevent 
the cleavage of aptamers by endonucleases. this type 
of modification is typically used to protect escort rnA 
aptamers, whereas  escort DnA aptamers are more 
frequently used without any additional modifications. 
the major pathway of degradation of rnA aptamers in 
biological media is  cleavage by pyrimidine endoribonu-
cleases; therefore, as early as at the stage of construc-
tion of combinatorial rnA libraries for selecting escort 
aptamers, the pyrimidine nucleosides within them are 
substituted for their 2'-fluoro- and 2'-amino analogues 
by using the corresponding modified nucleoside triphos-
phates for synthesizing a library.  It is possible to use t7 
rnA polymerase [13] or its mutant version (capable of 
inserting these 2'-modified nucleoside triphosphates 
into rnA with  higher efficiency) to integrate them into 
a growing rnA strand [14]. there is also mutant rnA 
polymerase inserting 2'-O-methyl analogues of nucleo-
side triphosphates [15, 16]; however, due to the problems 
associated with the reaction of reverse transcription of 
2'-O-methyl-containing rnAs, the use of 2'-O-methyl-
rnA libraries directly during the selection process has 
not yet become common practice [4].
In order to obtain 2'-O-methyl-containing aptamers, 
a quantity of ribonucleotides within a rnA aptamer 
are substituted for their 2'-O-methyl analogues, after 
the aptamers have been selected and their nucleotide 
sequences determined. the introduction of 2'-O,4'-c-
methylene-linked bicyclic nucleotides (LnA – locked 
nucleic acids) is another way of increasing the stabil-
ity of  aptamers of a known sequence. this modifica-
tion is used both in rnA [17] and DnA aptamers [18]. 
A number of nucleotides can be substituted for a flex-
ible linker based on ethylene glycol for the purpose of 
minimizing the aptamer’s length and simultaneously 
increasing its resistance to endonucleases [18, 19]. cap-
Table 1. Comparison of the properties of NA aptamers and monoclonal antibodies
Aptamers Monoclonal antibodies
Selection method In vitro selection Hybridoma technology, including  
immunization of animals
Synthesis method chemical or enzymatic synthesis Produced using cell cultures  
or laboratory animals
Limitations imposed on the target 
molecules no limitations Antibodies against non-immunogenic  
or toxic substances cannot be obtained
Affinity to the target Kd ≈ 10–10–10–7 M Kd ≈ 10–10–10–7 M
Specificity High High
Stability can re-naturate after heat treatment; 
long-term storage is possible
Irreversible denaturation after heat treatment; 
higher sensitivity to storing conditions
Immunogenicity not shown High
Possibility of chemical  
modification Wide LimitedreVIeWS
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ping of the 3'-terminus with an additional thymidine 
residue linked via the 3'-3'-phosphodiester bond is used 
to prevent the cleavage of aptamers [17, 19].
researchers either use the modified nucleoside tri-
phosphates or modify the “ready-made” aptamers in 
order to introduce additional functional groups into an 
aptamer during the selection (see review [4]). In the 
case of escort aptamers, the introduction of an aliphatic 
amino or sulfhydryl group to the 5'- or 3'-terminus of 
an aptamer is the most common. It allows one to syn-
thesize the various conjugates of aptamers with toxins, 
antibiotics, fluorescent or photoreactive groups, nano-
particles, etc. (see Section Application of escort aptam-
ers).
It must be kept in mind that the introduction of mod-
ifications into a “ready-made” aptamer may result in 
considerable changes in its molecular conformation, as 
well as a decrease in the aptamer’s affinity to its target. 
therefore, in each case one must thoroughly select the 
type and position of these modifications. In addition, 
one must study the effect they have on the aptamer’s 
affinity to its target.
OBTAINMENT OF ESCORT APTAMERS
When selecting escort aptamers in vitro, the individual 
proteins from the cell surface or whole cells are used 
as targets. the use of cells as targets has a number of 
advantages over using purified proteins:
– no need for producing a pure protein to act as a 
target;
– the obtained aptamers possess high affinity to the 
target cells;
– the selection can be performed for the entire cell, 
even if a particular surface target protein is not known 
a priori; and
– the possibility to identify new, previously un-
known specific markers on the cell surface emerges.
the protocol for cell selection of escort aptamers has 
specific features. the high number of surface domi-
nants, which can either be unique for a definite cell 
type or be common to cells of various types, is one of 
the key problems that arise when using cells as targets. 
In order to eliminate the nonspecific aptamers binding 
to the molecular targets that are common to many cell 
types from the selection, an additional stage of coun-
ter-selection, or negative selection, is added to  SeLeX. 
thus, to select  aptamers that can bind to a certain pro-
tein on the cell surface, two cell lines are used: one of 
these cell lines (target cells) expresses the desired pro-
tein, whereas the second cell line (control “negative” 
cells) is represented by  cells of the same type that do 
not express this protein.  Sequential incubation of the 
nucleic acid library with the control cells and target 
cells enables one to select particular sequences that 
bind only to the desired protein on the cell surface .
the general scheme of cell selection of escort aptam-
ers (by the example of an rnA library) is provided in 
Fig. 3. the initial oligonucleotide library is incubated 
with control cells, and the unbound molecules are iso-
lated. they are then incubated with the target cells, 
and the unbound molecules are isolated again. After 
the cells have been disintegrated, the bound aptamers 
are extracted, amplified, and  subsequently used in the 
next round of selection.
the usage of cells as targets for in vitro selection was 
first described by K. Morris et al. [20]. DnA aptamers 
recognizing ghosts of human erythrocytes (haemoglob-
in-free cells that retain the same shape of the mem-
brane as  native erythrocytes) were obtained in that 
study. In order to produce aptamers, the ssDnA library 
was incubated with target cells. then, the bound se-
quences were isolated via filtration through nitrocel-
lulose filters. the resulting set of DnA molecules was 
amplified and used in the subsequent round of selec-
tion. After  25 selection rounds, two aptamer motifs 
comprised 25% of the total number of clones. Photoac-
tivatable phenyl azide groups introduced into these two 
aptamers were used to demonstrate that they bind to 
the cell surface of various molecular targets. the study 
was the first example of using combinatorial libraries 
of nucleic acids for the selection of aptamers targeted 
at such complex objects as the cell membrane.
2’-fluoro  2’-amino
2’-O-methyl  LNA
3’-3’-phosphodiester 
bond
Hexaethylene glycol linker
Fig. 2. Chemical modifications of sugar-phosphate 
backbone increasing the resistance of escort aptamers in 
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Aptamers recognizing malignant cells
the overwhelming majority of studies devoted to 
the selection of aptamers targeting  living cells have 
focused on the search for sequences that can specifi-
cally bind to malignant cells. to this end, S. Lupold et al. 
[21] described the obtainment of 2'-F-modified rnA 
aptamers capable of binding to prostate-specific mem-
brane antigen (PSMA). this protein is located on the 
cell membrane’s surface and is the marker of tumor 
cells of the prostate gland. the cells of healthy tissues 
are characterized by a very low level of PSMA, which 
considerably increases with the development of malig-
nant tumors. A recombinant protein corresponding to 
the extracellular domain of PSMA, rather than whole 
tumor cells, was used as a target. After six rounds of 
selection, two rnA sequences (A9 and A10) comprised 
95% of the enriched library. A 56-nt aptamer A10-3 
was obtained via minimization of the length of the A10 
aptamer; an additional thymidine residue was linked 
to the 3'-terminus of A10-3 via a 3'-3'-phosphodiester 
bond for the purpose of protection from exonucleases. 
this aptamer was shown to specifically bind to PSMA-
expressing LncaP cells, and not to bind to Pc-3 pros-
tate cancer cells, which do not express this protein.
c. Ferreira et al. [22–24] also described the use of the 
fragments of individual surface proteins in studies de-
voted to the selection of DnA aptamers against the tu-
mor marker surface glycoprotein mucin (Muc1). Mucin 
hyperexpression is typical of cancer cells. Immunogenic 
synthetic peptides (mucin fragments immobilized on 
a column with functionalized sepharose) were used as 
targets for the selection. After 10 rounds of selection, 
12 aptameric sequences were obtained, one of which 
(aptamer S1.3/S2.2) was capable of binding to mucin-
producing tumor cells [23]. the same method was used 
to produce an additional four DnA aptamers, although 
recombinant mucin was used as a target [22]. the third 
variant selected against the mucin mimetic compound, 
O-glycosylated peptide, proved to be the most success-
ful [24]. the DnA aptamer 5TRG2, which was obtained 
via this method, is characterized by the highest affinity 
to the target peptide (Kd = 18.6 nM) and is capable of 
not only selective binding to mucin on the cell surface, 
but also of penetrating into the cells via receptor-me-
diated endocytosis.
It is noteworthy that the selection against whole 
cells is considered to be the most reliable and efficient 
method for aptamer production. thus, D. Daniels et 
al. [25] described the selection of DnA aptamers ca-
pable of binding to the surface of glioblastoma u251 
cells. After 21 selection rounds, the resulting GBI-10 
aptamer, together with its homologues, comprised ap-
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proximately 10% of the entire quantity of the selected 
sequences. It was ascertained via affinity purification 
of the cell extract using the GBI-10 aptamer immobi-
lized on magnetic particles that this aptamer is targeted 
against tenascin c (tn-c), the protein located mostly in 
the extracellular matrix. Hyperexpression of this pro-
tein is typical of a wide range of tumors. Selection was 
carried out at 4°c in order to prevent the penetration 
of aptamers inside the cells and to reduce the degree of 
aptamer degradation. the apparent dissociation con-
stant of the aptamer–tenascin c complex was equal to 
150 nM under the said conditions, whereas the Kd value 
increased by an order of magnitude as the temperature 
rose from 4 to 37°c.
the considerably more stable complexes of 2'-F-
rnA aptamers against tenascin c were obtained using 
three in vitro simultaneous selection protocols. In the 
first and second cases, a recombinant protein and gliob-
lastoma u251 cells, respectively, were used as targets. 
In the third case, cross-selection was performed, which 
comprised two additional selection rounds with respect 
to the tn-c protein following the 9 rounds of selection 
with respect to glioblastoma cells [19]. All pyrimidine 
nucleosides within the rnA library were replaced by 
their 2'-F-analogues, in order to enhance their stabil-
ity in biological media. the aptamers selected via all 
three methods had an appreciably high affinity to 
tn-c (Kd = 1–10 nM). the aptamers obtained by selec-
tion against the individual protein and the aptamers 
obtained by selection against the cells contained simi-
lar sequences. the 55-nt aptamer TN-9 was truncated 
by 16 nucleotides; it also underwent several additional 
chemical modifications. namely, several nucleotides 
were substituted for a hexaethylene glycol linker; most 
purine residues were substituted for their 2'-O-methyl 
analogues; the 3'-terminus was capped with a thymi-
dine residue linked via a 3'-3'-phosphodiester bond; 
and amino groups were added to the 5'-terminus to 
produce bioconjugates. the resulting modified ТТА1 
aptamer (Fig. 4) retained a high level of affinity to the 
target protein (Kd = 5 nM) and was characterized by   
high biological stability.
W. tan et al. obtained DnA aptamers capable of 
binding to t-cell leukaemia ccrF-ceM cells [26]. 
Burkitt lymphoma B-cells (the so-called ‘ramos cells’) 
were used as controls  at the counter-selection stage. 
the resulting, highly affine aptamers were capable of 
not only  selective binding to the ccrF-ceM target 
cells, but also of recognizing these cells in a mixture 
containing other cancer cell lines and cells from the 
medullary fluid of healthy individuals [27]. It turned 
out that the 88-nt sgc8 aptamer with the highest af-
finity to the target cells (Kd = 0.8 nM) binds to protein 
tyrosine kinase 7 (PtK7) on its surface [28]. PtK7 par-
ticipates in signal transduction during the development 
and metastatic spread of malignant tumors. Moreover, 
the sgc8 aptamer is capable of penetrating into ccrF-
ceM cells, where it localizes in endosomes [29]. the 
C8FL aptamer containing 33 nucleotides and a linker 
and possessing  exceptional stability to serum nucle-
ases and  high affinity to target cells (Kd = 1.53 nM) was 
obtained via minimization of the nucleotide sequence 
of the sgc8 aptamer and the introduction of chemical 
modifications into its structure (Fig. 5) [18].
In 2009, A. ellington et al. [30] studied the specifi-
city of the binding of a number of cell aptamers. In 
particular, they demonstrated that  aptamers targeted 
at ccrF-ceM cells were capable of recognizing other 
types of malignant cells, which are typically capable 
of forming a monolayer. the authors assumed that 
'
' '
Fig. 4. The proposed secondary structure of the modified 
ТТА1 aptamer binding to tenascin C [19]. Designations: 
NF – 2’-fluoro-2’-deoxyribonucleotide, Nm – 2’-O-methyl-
ribonucleotide, NH2 – aminohexanol residue, L – hexaeth-
ylene glycol phosphate linker.
'
'
Fig. 5. The proposed second-
ary structure of the modified 
C8FL aptamer against CCRF-
CEM cells [18]. Designations: 
L – hexaethylene glycol phos-
phate, N* – LNA nucleotides.18 | ActA nAturAe |  VOL. 3  № 4 (11)  2011
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the aptamers obtained in the studies conducted by 
W. tan et al. [26–29] could specifically recognize not a 
definite type of leukaemia cells, but  cells capable of ad-
hesion. the following arguments are given to  support 
this assumption: 1) protein tyrosine kinase 7 partici-
pates in cell adhesion, 2) the ccrF-ceM cells capable 
of monolayer formation were used as targets during 
the selection, whilst the ramos cells, which do not form 
a monolayer, were used as a negative control. In other 
words, it was possible to select aptamers against the 
cells capable of adhesion. However, it should be not-
ed that it was the homologous sga16 aptamer, and not 
the sgc8 aptamer, that was used in the experiments 
described above. the affinity of the sga16 aptamer to 
the target cells is lower than that of sgc8 by an order of 
magnitude. Hence, one cannot unequivocally claim that 
all the aptamers obtained by W. tan et al. [26–29] are 
nonspecific to  ccrF-cFM cells.
W. tan et al. [31, 32] used ramos cells not only as   
control cells, but also as selection targets; in the latter 
case, the SeLeX cycle did not comprise the counter-
selection stage [31]. It was demonstrated that the im-
munoglobulin M heavy chain bound to the membrane 
acted as a molecular target for aptamers on the surface 
of ramos cells [32]. the tendencies of these aptamers to 
bind to the target cells only at low temperatures (the 
selection was carried out at 4°С) and their potential   
to bind not only to the cell surface of IgM, but also to 
the soluble IgM in blood plasma were their significant 
drawbacks. to solve this problem, the minimization of 
the structure of TD05 aptamer (truncation of the nu-
cleotide sequence from 48 to 37 nucleotides), combined 
with the substitution of four deoxyribonucleotides at 
the 3'-terminus for their LnA analogues, was per-
formed [33]. the truncated modified aptamers TD05.17 
were then used to design tri- and tetrameric constructs 
in which the aptameric sequences were linked by non-
nucleotide polyethylene glycol insertions (e.g., see 
Fig. 6). the resulting multimers were specifically bound 
to ramos cells at 37°С (Kd = 256 nM for the trimer and 
272 nM for the tetramer); they recognized heavy IgM 
chains and did not interact with soluble IgM.
W. tan et al. also obtained DnA aptamers capable of 
distinguishing between two closely related acute my-
eloid leukaemia cell lines [34], between small-cell and 
nonsmall-cell lung cancer cells [35], and between he-
patic cancer cells and normal hepatocytes [36].
M. Blank et al. [37] obtained DnA aptamers which can 
selectively recognize brain tumor micro-vessels in rats 
and do not bind to healthy vessels. During the study, 
the DnA library was first incubated with the control 
cells represented by n9 microglial cells (brain mono-
cytes), followed by  incubation with the target cells rep-
resented by rat YPen-1 immortalized endothelial cells 
transformed with the SV40 hybrid virus. Following the 
in vitro selection, the specificity of the binding of the 
target and control cells to each clone was determined 
and the histochemical staining of tumor vessels was 
performed. It turned out that the endothelial protein 
pigpen, whose synthesis  increases in migrating and ac-
tively dividing endothelial cells, is the molecular target 
for the most active III.1 aptamer (Fig. 7). the authors 
believe that this protein can be considered both as a 
new diagnostic angiogenesis marker and as a potential 
molecular target to block tumor angiogenesis.
In 2011, e. Zueva et al. published a study [38] devot-
ed to the search for aptamers capable of distinguish-
ing between highly mobile metastatic cells and malig-
nant cells with  low mobility. two lines of transformed 
Syrian hamster fibroblasts (the control line with  low 
' '
Fig. 6. The proposed secondary structure of the trimer 
formed by the modified TD05 .17 aptamer against Ramos 
cells [33]. Designations: L – hexaethylene glycol phos-
phate, N* – LNA nucleotides.
Fig. 7. The proposed secondary structure of DNA aptam-
er III .1 against microvessels of rat brain tumor [37].
'
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mobility and the target cells with  high mobility) were 
used to select 2'-F-containing rnA aptamers. Aptam-
ers Е10 and Е37 were capable of binding to metastatic 
cells with  high affinity and selectivity (Kd values were 
37 and 50 nM, respectively), and they were capable of 
suppressing cell migration at a concentration of 100 nM. 
the E10 aptamer was also capable of suppressing cell 
invasion.
J. Mi et al. [39] described the selection of aptamers 
against colorectal cancer cells with metastasis to the 
liver. It is noteworthy that model animals, rather than a 
cell culture, were used for the selection: a 2'-F-contain-
ing rnA library was intravenously injected into mice 
with a previously grafted liver tumor, followed by the 
extraction of the bound 2'-F-rnA from the liver. After 
it was intravenously injected to mice, the 14-16 aptamer 
was selectively bound to intraliver tumors. this aptamer 
was capable of penetrating into tumor cells and binding 
with helicase p68 in the nucleus and cytoplasm (hyper-
expression of helicase p68 being typical of colorectal can-
cer). thus far, this study is the only example of aptamer 
selection using multicellular organisms.
Aptamers binding to the surface receptors of  cells
cell receptors are considered to be an attractive thera-
peutic target. they can be neutralized by the action of 
aptamers blocking  ligand-induced activation. Design-
ing aptamers capable of  specific blockade of certain 
receptors and the subsequent “switching-off” of the 
corresponding signal pathways provides the opportu-
nity both to study the molecular mechanisms of their 
function and to investigate the diagnostics and thera-
py of different diseases. Several research groups have 
managed to obtain  aptamers capable of binding to cell 
receptors.
recombinant proteins corresponding to the extracel-
lular domains of receptors have been used as targets 
to obtain receptor-recognizing aptamers. the method 
was used to obtain 2'-fluoro-containing rnA aptamers 
capable of recognizing rat cD4 receptors [40], human 
cD4 receptors [41], and mouse ctLA-4 receptors [42]. 
c. chen et al. [43] described the production of aptam-
ers against the mouse transferrin receptor.  Fluores-
cently labelled rnA and DnA aptamers conjugated to 
streptavidin were used to demonstrate the ability of 
aptamers to penetrate into cells via endocytosis. Mean-
while, aptamer binding to the transferrin receptor had 
no effect on the interaction between this receptor and 
transferrin, since these aptamers can be used for the 
delivery of therapeutics without blocking the functions 
of the receptor necessary for the vital activity of the 
cells.
using the cell-SeLeX method  with a counter-selec-
tion stage, 2'-F-containing rnA aptamers against the 
human transforming growth factor β (tGF-β) receptor 
type III (tbrIII)(expressed on the surface of chinese 
hamster ovary (cHO) cells) were selected [44]. In the 
study,  parent cHO cells that do not express this pro-
tein were used at the negative selection stage. the А07 
aptamer (Fig. 8) that is capable of selective binding to 
the receptor tbrIII and forms with it a stable complex 
(Kd = 2.47 nM) was obtained via selection. this aptamer 
was also shown to be capable of inhibiting  association 
between the receptor tbrIII and its ligand, tGF-β2.
L. cerchia et al. [45] described the selection of 
2'-F-rnA aptamers that bind to the mutant dimeric 
form of the human receptor tyrosine kinase retc634Y, 
which is typically present upon multiple endocrine 
neoplasia type 2. During the selection, the library was 
incubated with  cells expressing the mutant form of 
receptor retc634Y (Pc12/Men2А). At the counter-
selection stage, the oligonucleotide library was incu-
bated with two types of control cells, the “parent” cells 
Pc12 that did not express the target protein and the 
Pc12/Men2B cells that had a morphology similar to 
that of Pc12/Men2А but expressed the monomer-
ic form of receptor tyrosine kinase retМ918Т. the D4 
and D24 aptamers obtained after 15 selection rounds 
were capable of efficiently binding to the target cells 
(Kd = 40 nM) and suppressing the activity of ret by 
70% at a concentration of 200 nM. It should be noted 
that the D4 aptamer was also capable of binding to 
Pc12/Men2B cells, although the degree of binding was 
considerably lower (by a factor of approximately 2.5 as 
compared with that of the target cells Pc12/Men2А).
unfortunately, the use of  cross-selection to obtain 
aptamers against the receptor retc634Y (seven rounds 
of selection for Pc12/Men2А cells and four rounds 
of selection for the purified recombinant protein [46]) 
'
Fig. 8. The proposed secondary structure of RNA aptamer 
А07 against the human transforming growth factor recep-
tor [44]. Designations: NF – 2’-fluoro-2’-deoxyribonucle-
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failed to yield better results. the obtained E38 aptamer 
had a considerably different structure in comparison 
with that of the aptamers against the target cells and 
was characterized by lower affinity to Pc12/Men2А 
cells (Кd = 100 nM). It was also incapable of inhibiting 
the activity of the receptor tyrosine kinase.
Aptamers capable of recognizing 
undifferentiated cells
the production of aptamers that can bind to undiffer-
entiated cells is challenging. c. Wang et al. [47] selected 
DnA aptamers capable of distinguishing between dif-
ferentiated Pc12 cells and the undifferentiated “par-
ent” cells that were used as the control cells at the 
counter-selection stage. Six selection rounds were suf-
ficient to obtain aptamers that were capable of recog-
nizing the differentiated cells and did not bind to the 
undifferentiated cells. Aptamers against undifferen-
tiated cells types, e.g., against stem cells, can be used 
for cell isolation and purification in regenerative medi-
cine, which is a rapidly developing field of medicine. 
the studies conducted by K. Guo et al. [48, 49] were 
devoted to the creation of DnA aptamers for cell isola-
tion and immobilization. In particular, DnA aptamers 
capable of binding to mature mesenchymal stem cells 
were obtained [49]. After 12 selection rounds without 
counter-selection,  aptamers capable of selectively rec-
ognizing the target cells, among other medullary cells, 
were obtained; the possibility of  using them to iso-
late stem cells from  bone marrow was demonstrated. 
J. Hoffmann et al. [50] produced DnA aptamers capa-
ble of binding to the precursors of porcine endothelial 
cells, which were subsequently used to immobilize the 
cells on the surface of polytetrafluoroethylene or poly-
dimethylsiloxane disks (see Section Application of es-
cort aptamers).
Identification of new biomarkers via 
the cell selection of aptamers
the in vitro selection of aptamers using living cells ena-
bles to identify new biomarkers typical for cells of a 
definite type, after the aptamers have been selected 
and the surface proteins binding to these aptamers 
have been revealed. existing methods for searching 
for biomarkers (Western blotting, screening of mrnAs 
using quantitative Pcr or chips, 2D electrophoresis 
coupled with mass spectroscopy) are not sufficiently 
efficienct; their common drawback being the possibil-
ity of false positive and false negative results, which 
often occurs. the general strategy for the search for 
biomarkers using aptamers (AptaBiD, Aptamer-facil-
itated Biomarker Discovery) formulated by M.V. Be-
rezovski et al. [51] enables to overcome these difficul-
ties. the probability of obtaining false positive results 
decreases through multiple selection rounds, which 
eliminate the impact of such random factors as the sto-
chastic differences between cells of the same type and 
unintended variations at all stages of cell treatment. 
Meanwhile, the exponential enrichment of the library 
during the selection allows to reveal even insignificant 
distinctions between the control cells and the target 
cells, if they are retained from round to round. this re-
duces the probability of obtaining false negative results. 
to confirm the high potential of the AptaBiD strategy, 
it was used to search for biomarkers determining the 
differences between mature and immature dendritic 
cells. As a result, both previously known biomarkers 
of dendritic cells and six new biomarkers of immature 
dendritic cells were revealed. A significant feature of 
this method worth noting is that it does not involve the 
cloning and sequencing stages; the enriched librar-
ies, rather than individual aptamers, are used for the 
search for biomarkers. thus, the process becomes both 
quicker and cheaper.
Aptamers recognizing the surface 
proteins of microorganisms
In addition to cultured cells, pathogenic microorgan-
isms can also be used as targets for cell selection. the 
aptamers obtained via this method can be subsequently 
used in the diagnostics and therapy of infectious dis-
eases, as well as for the quantitative determination of 
microorganisms.
M. Homann and H. Göringer [52] obtained rnA 
aptamers capable of binding to the living trypanosomes 
Trypanosoma brucei, parasitic protozoans causing the 
sleeping sickness. two Tr. brucei strains were used as 
targets for the selection. the rnA library was incu-
bated with parasitic organisms that were present at 
the bloodstream stage; the unbound molecules were re-
moved via centrifugation. the resulting aptamers were 
capable of binding to the organisms of both strains at 
the bloodstream stage (Kd = 60 nM), whilst being in-
capable of recognizing Tr. brucei at other stages of 
development. the methods of photoaffinity modifica-
tion and fluorescent microscopy with the fluorescent-
labelled aptamer 2-16 were used to ascertain that the 
protein with a molecular weight of 42 kDa located in 
the trypanosome flagellar pocket acts as a target for 
this aptamer. After binding to this protein, the aptamer 
penetrates into the trypanosome via receptor-medi-
ated endocytosis and is subsequently located in endo-
somes. As shown by the example of the 2-16 aptamer 
conjugated with biotin, these aptamers can be used to 
deliver other substances into trypanosomes [53]. Py-
rimidine nucleosides were replaced by their 2'-amino 
or 2'-fluoro analogues in order to increase the stabil-
ity of the 2-16 aptamer in biological media. As a result reVIeWS
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of the modification, the aptamer containing 2'-nH2 
groups lost its ability to bind to trypanosomes; in con-
trast, the 2'-F-modified aptamer retained its affinity 
to these organisms (Kd = 70 nM) and was characterized 
by high resistance to serum nucleases [54]. the use of 
modified rnA libraries containing 2'-fluoro or 2'-amino 
pyrimidine nucleotides during the selection was more 
successful. Living trypanosomes were used as targets 
when selecting 2'-amino-containing rnA aptamers. 
the resulting aptamer possessed affinity to trypano-
somes, being virtually equal to that of the 2-16 aptamer 
(Kd = 70 nM), and bound to these organisms within the 
limited area around the flagellum [55]. Selection against 
the purified surface protein sVSG was used to obtain 
2'-F-containing rnA aptamers capable of binding to 
the entire trypanosome surface [56, 57].
2'-F-rnA aptamers against another type of trypano-
somes (Tr. crusi, the agent of chagas disease) were also 
obtained [58]. At the trypomastigote stage, Tr. cruzi 
bind to the host cells and penetrate into them through 
interaction with the extracellular matrix proteins of 
the host cells. 2'-F-pyrimidine-containing rnA aptam-
ers at a concentration of 1 µM blocked the penetration 
of these parasitic organisms into the cells by 50–80%.
 Aptamers capable of binding to different types of 
bacteria generate significant interest. thus, the selec-
tion of DnA aptamers with respect to the causative 
agent of tuberculosis Mycobacterium tuberculosis was 
performed [59]. A single introduction of 0.8 µg of the re-
sulting NK2 aptamer resulted in a decrease in the num-
bers of microbacteria in tuberculosis-infected mice, al-
leviated disease presentations, and also increased the 
lifetime [59]. the potential use of the NK2 aptamer in 
tuberculosis therapy is assumed.  Aptamers capable of 
specific binding to the spore surface of the causative 
agent of anthrax Bacillus anthracis [60] and crystal-
forming bacteria B. thuringiensis [61], salmonellae Sal-
monella enterica [62] and S. typhi [63], staphylococci 
Staphylococcus aureus [64], lactic acid bacteria Lacto-
bacillus acidophilus [65], Escherichia coli [66, 67], and 
Campylobacter jejuni bacteria [68] have also been ob-
tained.
 escort aptamers capable of binding to “foreign” 
proteins located on the surface of infected cells should 
be considered separately. A. Barfod et al. [69] obtained 
aptamers against the PfeMP1 protein, which is ex-
pressed on the surface of erythrocytes infected with 
the malaria parasite Plasmodium falciparum. this pro-
tein facilitates erythrocyte aggregation (formation of 
the so-called ‘rosettes’) and adhesion of the infected 
erythrocytes to the walls of minute blood vessels. the 
recombinant DBL1α protein (the semi-conserved n-
terminal domain of the PfeMP1 protein responsible 
for rosettes formation) was used as a target for the se-
lection of 2'-F-pyrimidine-containing rnA aptamers. 
the resulting aptamers at a concentration of 387 nM 
(12 µg/ml) caused the almost complete disintegration 
of rosettes in a cell culture, which allows one to view 
them as potential anti-malaria agents.
2'-F-rnA aptamers against gp120, the human im-
munodeficiency virus type 1 (HIV-1) coat protein, were 
obtained by selection with respect to the recombinant 
protein; these aptamers were capable of binding to 
gp120 on the surface of the infected cells (see review 
[7]).
F. chen et al. [70] described a procedure for obtain-
ing DnA aptamers against the e2 protein expressed on 
the cell surface (the hepatitis c virus coat protein). the 
same cell line incapable of expressing this protein was 
used for counter-selection. Among the resulting series 
of aptamers, the ZE2 aptamer possessed the highest 
affinity to the surface protein (Kd = 1 nM) (Fig. 9). At a 
concentration of 100 nM, this aptamer was both capa-
ble of binding to viral particles, as well as blocking their 
fusion with cells. these results enable one to assume 
that the ZE2 aptamer can potentially be used both for 
the diagnostics of hepatitis c and for the treatment of 
patients suffering from this disease, as well as for stud-
ying the virus-cell interactions.
the following section describes the design of systems 
centred on the cell delivery of therapeutic agents, di-
agnosing various diseases, and determining the path-
ogenic microorganisms in the environment and food 
products based on escort aptamers.
APPLICATION OF ESCORT APTAMERS
numerous multifunctional constructs have been de-
signed on the basis of escort aptamers, where an aptam-
er acts as a directing component ensuring the specific 
recognition of cells or target tissues. the aptamers that 
'
'
Fig. 9. The proposed secondary structure of DNA aptam-
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are capable of penetrating into cells via receptor-me-
diated endocytosis after they bind to the surface pro-
teins can be used as a platform to design highly specific 
therapeutic agents that can impose targeted action on 
cells of a definite type. Another actively developing 
direction in the application of escort aptamers is their 
use in the design of a highly precise diagnostic system 
enabling the detection of target cells, among other 
cells, in the organism. the schematic presentation of 
the major types of conjugated escort aptamers that are 
currently being used to deliver therapeutic agents to 
cells and perform specific cell detection is provided in 
Fig. 10. the data on the application of escort aptamers 
are briefly summarized in Table 2.
The use of escort aptamers to deliver various 
therapeutic agents to cells
the anti-PSMA-aptamers A9 and A10, which bind to 
the prostate-specific membrane antigen, are among 
the most popular candidates for the design of a deliv-
ery systems [20]. PSMA is capable of penetrating into 
cells via clathrin-mediated internalization [97]; hyper-
expression of this protein is a characteristic feature of 
many tumors. It was a combination of these factors that 
led to the significant interest pertaining to the use of 
anti-PSMA-aptamers as an addressing fragment in the 
delivery of various anti-tumor agents into cells. thus, 
the conjugation of anti-PSMA-aptamer A9 with the 
protein toxin gelonin resulted in a ~180-fold increase 
Delivery to cells
Conjugates with 
biodegradable 
nanoparticles containing 
chemotherapeutic 
agents
Conjugates with  
Au/Ag nanorods
Conjugates with  
chemotherapeutic agents
Conjugates 
with siRNA
Conjugates with 
dendrimers
Conjugates with photoagents
Conjugates containing  
radionuclides Escort aptamers
Conjugates with carbon  
nanotubes
Conjugates with  
Au nanoparticles
Conjugates  
with quantum dots
Conjugates  
with fluorofores
Specific cell detection
Fig. 10. The main types 
of conjugates of escort 
aptamers used for tar-
geted cell delivery and 
specific cell detection.reVIeWS
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Table 2. Escort aptamers and their use for the delivery of various therapeutics into cells and for specific cell detection
Aptamer target Selection method Application
2'-F-rnA
Prostate-specific 
membrane anti-
gen (PSMA)
Selection  against recom-
binant protein – extracel-
lular domain of PSMA [21]
Delivering gelonin [71] and doxorubicin [72] into 
LncaP tumor cells.
Delivering sirnA into LncaP cells [74–77].
Delivering nanoparticles containing antitumor thera-
peutic docetaxel into LncaP cells [82–84].
Imaging of LncaP cells using aptamer-conjugated 
gold nanoparticles [92] or aptamer-conjugated lumi-
nescent cdSe–cdte crystals [90].
electrochemical detection of prostate cancer cells using 
an aptamer immobilized on an Au-electrode [91].
Detection of PSMA on LncaP cell surface via proximity 
ligation assay [96]
DnA Protein tyrosine 
kinase 7 (PtK7)
Selection against the ccrF-
ceM cells (the precursors 
of t-cell acute myeloid 
leukaemia cells) [26]
Delivering doxorubicin [73], Au/Ag nanorods [80, 81], 
and poly(amidoamine)-based dendrimers [87] into 
ccrG-ceM cells .
Investigation of the distribution of PtK7 receptors 
over the cell surface using aptamer–fluorescein 
conjugates [93].
reversible fluorescent labelling of ccrF-ceM cells 
using aptamer-conjugated quantum dots Qdot525 [94]
2'-F-rnA rat cD4 receptor Selection against recom-
binant protein [40] Delivering sirnA into cells [78]
2'-F-rnA HIV-1 coat 
protein
Selection against recom-
binant protein gp120 [79] Delivering sirnA into HIV-1-infected cells [7, 79]
DnA Mucin (Muc1)
Selection against synthetic 
peptides (mucin fragments) 
[23, 24]
Photodynamic therapy using photoreactive conjugates 
of the aptamer and chlorine e6 [24].
tumor imaging using radioactive isotopes (99tc) [88]
DnA, rnA Mouse transferrin 
receptor (tfr)
Selection against recom-
binant protein – extracel-
lular domain of tfr
Delivering lysosomal enzymes into cells to treat lyso-
somal storage diseases [43]
2'-F-rnA tenascin c
cross-selection using a 
recombinant protein and 
u251 cells [19]
tumor imaging using radioactive isotopes (99tc) [89]
DnA Membrane-bound 
IgM heavy chain
Selection against Burkitt 
lymphoma B-cells (ramos 
cells) [31]
Micelles for delivering various pharmaceutics into cells 
[86].
test strips based on TD05 and TE02 aptamers for the 
detection of ramos cells in blood samples [95]
DnA B. thuringiensis 
bacteria
Selection against B. thuring-
iensis spores
Detection of B. thuringiensis spores using aptamer-
conjugated cdSe-ZnS quantum dots [61]
rnA E. coli bacteria Selection against E. coli 
DH5α strain [67]
Potentiometric detection of E. coli using aptamers-
conjugated carbon nanotubes [67].
Detection of E. coli via quantitative rt-Pcr of rnA 
aptamers bound to the bacteria [98]
rnA S. typhi bacteria
Selection against the major 
protein of S. typhi microvilli 
[63]
Potentiometric detection of S. typhi using aptamer-
conjugated carbon nanotubes [97]
DnA Mesenchymal 
stem cells
Selection against porcine 
mesenchymal stem cells [49]
Isolation of stem cells from bone marrow using aptam-
ers immobilized on magnetic particles; cell sorting 
using fluorescent aptamer conjugates [49]
DnA
Precursors of 
porcine endothe-
lial cells
Selection against cD31-
positive cells from porcine 
blood [50]
Immobilization, growth, and differentiation of the pre-
cursors of endothelial cells on the surface of disks with 
immobilized aptamers (a model of vascular implants) 
[50]24 | ActA nAturAe |  VOL. 3  № 4 (11)  2011
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in cytotoxicity with respect to the target cells, in com-
parison with that for unbound gelonin (Ic50 = 27 nM for 
the conjugate and 5 µM for gelonin) [71]. Meanwhile, 
in the case of control cells incapable of expressing the 
PSMA protein, the cytotoxicity of the aptamer-gelonin 
conjugate was lower than that of the unbound gelonin 
(Ic50 = 15 µM), which attests to the fact that this con-
jugate is highly selective. V. Bagalkot et al. [72] used 
the A10 anti-PSMA-aptamer to deliver doxorubicin 
into cells. the anthracycline antibiotic agent doxoru-
bicin is used for the therapy of a wide range of diseases, 
such as leukaemia, malignant lymphomas, sarcomas, 
and cancers of various etiologies. However, the draw-
backs include toxic side effects, in particular, cardio-
toxicity. the ability of doxorubicin to intercalate be-
tween the base pairs of double-stranded nucleic acids 
was used to obtain the conjugates [72]. the intercala-
tion of doxorubicin into a double-stranded fragment of 
the A10 aptamer yielded non-covalent conjugates. the 
cytotoxicity of these conjugates with respect to LncaP 
target cells was comparable to that of unbound doxo-
rubicin of the same concentration (Ic50 = 5 µM). the 
cytotoxicity of conjugates with respect to Pc3 control 
cells was significantly lower. the sgc8с escort aptamer 
(“truncated” variant of the sgc8 aptamer) was used to 
deliver doxorubicin into human leukemic lymphob-
lasts (ccrF-ceM cells). Y. Huang et al. [73] obtained 
the doxorubicin–sgc8c aptamer conjugate, with doxo-
rubicin bound to the 5'-terminus of the aptamer via an 
acid-labile hydrazone bond that was hydrolyzed after 
the conjugate had penetrated into the cell. It has been 
shown that these conjugates can selectively penetrate 
into ccrF-ceM cells via receptor-mediated endocy-
tosis; their cytotoxicity with respect to ccrF-ceM 
cells being comparable to that of unbound doxorubicin 
(Ic50 = 0.3 µM). As opposed to unbound doxorubicin, 
the aptamer-doxorubicin conjugate showed no toxicity 
with respect to the control ramos cells. thus, binding 
of escort aptamers to chemotherapeutic agents makes 
it possible to reduce their toxic effects on tumor cells 
only. It can be anticipated that these conjugates will 
be used to design novel agents for anti-tumor chemo-
therapy with minimum adverse effects.
escort aptamers were also used to deliver small in-
terfering rnA (sirnA) into cells. Several types of con-
structs to deliver sirnA were designed on the basis of 
anti-PSMA-aptamers. the tetrameric biotin-strepta-
vidin complex containing two biotinylated strands 
of the A9 aptamer and two biotinylated sirnA mol-
ecules targeted against mrnAs of the lamin A/c or 
GADPH genes (Fig. 11A) was used to deliver sirnAs 
into PSMA-positive tumor cells [74]. these complexes 
could penetrate into cells without the use of transfect-
ants. At a concentration of 22.5 nM, they suppressed 
target gene expression by 50–80%; the efficiency of the 
suppression was identical to that of the corresponding 
sirnAs delivered into cells using Oligofectamine. the 
chimeric constructs were designed which consisted of 
a joint nucleotide sequence containing the A10 aptamer 
and one of the sirnA strands with the complementary 
second sirnA strand (Fig. 11B) [75]. At a concentration 
of 400 nM, these constructs can penetrate into PSMA-
positive cells without transfectants and almost com-
pletely suppress the expression of the bcl2 and plk1 tar-
get genes. With the aim of optimizing the structure of 
chimeric constructs, the targeting aptamer was trun-
cated from 71 down to 39 nucleotides, which simpli-
fied the chemical synthesis of both components of the 
construct. A number of modifications increasing the 
specificity and efficiency of the interaction with the 
mrnA target were introduced into the sirnA struc-
ture. A polyethylene glycol residue with a molecular 
weight of 20 kDa was bound to the sirnA passenger 
strand, which increased the half-circulation time of the 
chimeric constructs in mouse blood from 35 min to 30 h. 
the obtained preparation resulted in a considerable re-
gression of the PSMA-positive tumor in mice after the 
injection of five 0.25 nmol doses [76].
Another variant of a chimeric construct contain-
ing two molecules of anti-PSMA-aptamer A10-3 was 
А
b
siRNA siRNA
siRNA
   Streptavidin
Bio Bio
Bio Bio
Anti-PSMA-aptamer 
A9
Anti-PSMA-aptamer 
A10
Fig. 11.  Schematic representation of chimeric constructs 
for siRNA delivery into PSMA-positive cells. A. The 
conjugate of biotinylated anti-PSMA aptamer and siRNA 
connected via streptavidin [74]. B.  Chimeric RNA built 
from an anti-PSMA aptamer and siRNA [75]. Bio – biotin 
residue.reVIeWS
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described in [77]. In this construct, one of the sirnA 
strands targeted against mrnA of the eukaryotic elon-
gation factor 2 (eeF2) is inserted between two apta-
meric sequences, the second strand being complemen-
tary [77]. At a concentration of 2 µM, these conjugates 
caused suppression of the growth of the target cells by 
95%, with no impact on the growth of PSMA-negative 
control cells.
An interesting construct containing the “address-
ing” aptamer and sirnAs was described in [78]. Phage 
φ29 rnA capable of multimeric complex formation 
via  interaction between rnA loops was used to design 
these constructs. A phage rnA fragment was bound 
to each component of the construct, i.e., to the aptamer 
recognizing the cD4 receptor [40], to sirnAs targeted 
against the mrnAs of various apoptotic factors, and to 
the fluorescent dye. At a concentration of 100 nM, the 
resulting trimers containing an aptamer, sirnA, and 
a reporter group were able to penetrate into the cD4-
positive cells and inhibit the expression of the target 
genes.
chimeric constructs [7, 79] designed according to the 
principle proposed by J. Mcnamara et al. [75] and con-
sisting of a 2'-F-rnA-aptamer recognizing the viral 
protein gp120 on the cell surface and sirnA targeted 
against the Тat/Rev of HIV-1 rnA were used to act 
upon HIV-1 infected cells. these constructs (at a con-
centration of 400 nM) have the ability to inhibit HIV-1 
replication in a cell culture [79]. the use of these con-
structs to suppress HIV-1 replication in  mice has also 
been reported [7].
the sgc8c aptamer conjugated with Au-Ag nanorods 
was used to impose photothermal action on leukaemia 
cells [80, 81]. the nanorods are heated to 50°c under 
laser irradiation, which results in cell death through 
thermal shock. Aptamers conjugated with nanorods 
(approximately 80 aptameric molecules were bound to 
a nanorod) were capable of selective penetration into 
the target cells; approximately 90% of the cells died af-
ter exposure to radiation [81].
 reactive agents for photodynamic therapy (aptam-
ers covalently conjugated to chlorine e6) have been de-
signed on the basis of aptamers capable of binding to 
the surface protein mucin [24]. these conjugates can 
selectively penetrate into mucin-expressing tumor cells 
and cause their death after exposure to radiation; the 
efficiency of the conjugates was 500-fold higher than 
that of unbound chlorine. Meanwhile, the conjugates 
showed no toxicity towards healthy cells.
the DnA aptamer against mouse transferrin re-
ceptor was used to deliver the lysosomal enzyme α-L-
iduronidase into cells [43]. It was demonstrated that the 
aptamer-enzyme conjugates penetrated into mouse 
fibroblasts deficient in this enzyme and were further 
transported to lysosomes, where the introduced en-
zyme was capable of both functioning and facilitating 
the recovery of the cell metabolism. the results ob-
tained make aptamers against the transferrin receptor 
conjugated with lysosomal enzymes promising thera-
peutic agents for the treatment of diseases associated 
with the lysosomal function disorder.
Various carriers bound to the addressing aptamers 
are also used to ensure specific delivery of therapeutic 
agents. thus,  nanoparticles composed of the copolymer 
of lactic acid and glycolic acid (PLGA) with encapsulat-
ed docetaxel were covalently bound to the molecule of 
anti-PSMA-aptamer A10 [82–84]. the resulting conju-
gate was capable of specific binding to LncaP cells ex-
pressing the PSMA protein and penetrating into them 
[82, 85]. Mice with a grafted prostate tumor were used 
to demonstrate that anti-PSMA-aptamers conjugated 
with nanoparticles based on PLGA containing docetax-
el can efficiently suppress tumor growth and can even 
result in complete remission [83].
the construction of micelles based on the TD05 
aptamer with the stearic acid bound to it was described 
in [86]. these micelles were characterized by increased 
affinity to the target cells in comparison with that of 
the individual TD05 aptamer, and they were capable 
of specific penetration into the cells. It is not anticipated 
that these micelles will be used further to deliver ther-
apeutics into cells.
J. Zhou et al. [87] proposed using polyamidoamine 
(PAMAM) dendrimers as carriers for therapeutic de-
livery [87].  Sgc8c aptamer-conjugated dendrimers 
proved capable of selective and efficient binding to 
ccrF-ceM cells and penetrating into them. the size 
of the aptamer-dendrimer conjugate is approximately 
8 nm, the optimal size for using these conjugates as a 
platform for the delivery of therapeutic agents.
thus, the use of aptamers for targeted delivery of 
nanoparticles with anti-tumor agents into tumor tis-
sues is a promising avenue in the development of novel 
anti-tumor therapeutic strategies.
The use of escort aptamers for specific cell detection
the capability of escort aptamers to selectively recog-
nize cells of a definite type enables one to use them to 
design highly specific detection systems. the introduc-
tion of different types of labels into aptamers allows 
one to use them for cell detection in cultures, biological 
samples, and in living multi-cellular organisms. thus, 
radio-labeled aptamers have been used for tumor im-
aging in mice.  conjugates of the anti-tenascin aptamer 
TTA1 and anti-mucin aptamers with chelating agents 
capable of binding to 
99tc were used for the imaging 
of glioblastoma and breast cancer xenografts in mice 
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Various systems for detecting prostate cancer have 
been designed on the basis of anti-PSMA-aptamers. 
t. chu et al. [90] obtained the anti-PSMA-aptamer A9 
conjugated with luminescent cdSe/cdte crystals (the 
so-called quantum dots) for the imaging of PSMA-pos-
itive cells. these conjugates could bind to LncaP cells 
distributed over the model tissue (3D collagen matrix) 
with high levels of efficiency and specificity.  “Double” 
constructs consisting of the anti-PSMA-rnA-aptamer 
A10 and the peptide aptamer against PSMA-negative 
cells immobilized on a gold electrode were used for the 
electrochemical detection of two types of prostate can-
cer cells: those that contained PSMA on their surface 
(PSMA-positive) and those that did not contain the 
protein (PSMA-negative) [91]. D. Javier et al. [92] in-
troduced additional oligonucleotide fragments, which 
were complementary to 24-membered oligonucle-
otides covalently bound to gold nanoparticles, into anti-
PSMA-aptamers in order to perform the imaging of 
PSMA-positive cells. the binding of these complexes 
to PSMA on the cell surface was observed by reflected 
light detection using a confocal microscope.
DnA-aptamer sgc8 conjugated to fluorescein was 
used to study the distribution of the receptors of PtK7 
over the cell surface via fluorescence correlation micro-
scopy [93]. A new method for the reversible fluorescent 
labelling of live cells was proposed in [94] and was il-
lustrated by the example of ccrF-ceM cells. Aptam-
er sgc8 conjugated with the quantum dot Qdot525 se-
lectively bound to cells; after treatment with DnAse, 
the conjugates were completely removed from the cell 
surface, whereas the cells retained their viability. Flu-
orescence-activated cell sorting, enabling the rapid and 
efficient isolation of cells of a definite type, is a promis-
ing application of this method. Fluorescence-activated 
sorting of stem cells using aptamer–fluorescein conju-
gates was also described by K. Guo et al. [49]
Aptamers TD05 and TE02 targeted against ramos 
lymphoma cells were used when designing biosensor 
test strips for the rapid determination of malignant 
cells circulating in the blood stream [95]. the test zone 
of the biosensor contains the TD05 aptamer conjugat-
ed with gold nanoparticles. these conjugates form col-
oured complexes with ramos cells, which subsequently 
migrate along the strip until they are captured in the 
indicator zone of the biosensor through the binding of 
ramos cells to the immobilized TE02 aptamer. As a re-
sult, a characteristic red band is generated. these bio-
sensors can be used for cell detection directly in blood 
samples; a visual qualitative assessment or quantitative 
determination can be performed using a portable scan-
ner.
the use of a so-called ‘proximity ligation assay’ was 
proposed as means to detect the PSMA protein on the 
cell surface (Fig. 12) [96]. the system is composed of 
A9 aptamers containing additional oligonucleotide 
fragments on their 3'- or 5'-termini,  DnA probes that 
are complementary to each fragment, and the splint 
oligodeoxyribonucleotide, which is partially comple-
mentary to each DnA probe. Since PSMA is a dimer, 
when aptamers bind to PSMA on the cell surface, DnA 
probes become sufficiently close that they can be bound 
by a splint oligomer via the formation of a complemen-
tary complex. the DnA probes within this complex 
are then ligated; subsequently, real-time Pcr is used 
to detect the resulting dsDnA. this method is highly 
sensitive and enables the detection of 10 LncaP cells 
Detection of dsDNA  
via RT-PCR
Ligation
Splint oligonucleotide
DNA probe DNA probe
5’-lengthened 
aptamer
3’-lengthened 
aptamer
 PSMA
LNCaP cell
5' 3'
Fig. 12. Detection of prostate-specific membrane antigen 
using anti-PSMA aptamers by the proximity ligation assay 
[96]. The method includes the following stages: 1) forma-
tion of the complementary complexes of aptamers with 
DNA probes; 2) binding of aptamers to the adjacent sites 
on the cell surface, thus positioning DNA probes closer to 
each other; 3) hybridization of both DNA probes with the 
splint oligonucleotide; 4) ligation of DNA probes in the re-
sulting complex; 5) detection of dsDNA via real-time PCR.reVIeWS
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(prostate cancer) in the presence of 105 HeLa cells that 
do not contain the PSMA protein on their surface.
It was recently suggested that the aptamers bind-
ing to bacteria can be used for the design of biosensors 
for use in the detection of pathogenic microorganisms. 
DnA aptamers with bound cdSe-ZnS quantum dots 
were used for the fluorescent detection of B. thuring-
iensis [61]. rnA aptamers immobilized on the surface 
of single-walled carbon nanotubes were used to de-
sign potentiometric biosensors to determine E. coli [67] 
and S. typhi [97] and to demonstrate that they can be 
used for selective detection of these bacteria. A method 
based on the quantitative rt-Pcr of rnA aptamers 
bound to bacteria immobilized on magnetic particles 
was developed for the detection of E. coli [98]. novel 
aptamer-based biosensors could be used for highly se-
lective determination of bacteria in the environment 
and food products and for diagnosing infectious dis-
eases.
Another promising direction in the use of escort 
aptamers is the selective isolation of cells and cell im-
mobilization. thus, a system for the selective isolation 
of stem cells from bone marrow was designed on the 
basis of magnetic particles conjugated with aptam-
ers capable of binding to porcine stem cells [49]. DnA 
aptamers capable of binding to the precursors of por-
cine endothelial cells were immobilized on the surface 
of polytetrafluoroethylene or polydimethylsiloxane 
disks [50]. It turned out that aptamer-coated disks can 
be used to selectively isolate endothelial precursor cells, 
which can be subsequently differentiated into vascular 
endothelial cells while remaining bound to the disks. 
the assumption is that this approach could be used for 
the epithelialization of vascular implants, thus reducing 
the risk of implant rejection.
CONCLUSIONS
A number of escort aptamers capable of specific and ef-
ficient binding to cells of a definite type were recently 
obtained and approaches have been developed aimed 
at enhancing the stability of escort aptamers. It has 
been demonstrated that escort aptamers can be used to 
design efficient and highly specific systems for the de-
livery of therapeutic agents into cells, for the detection 
of cells of a definite type, for cell sorting, and for the 
selective blockage of surface proteins. Year after year, 
the number of studies devoted to the selection and ap-
plication of escort aptamers against various cell tar-
gets (from bacteria to stem cells) steadily increases. It 
should be noted that the selection of aptamers against 
living cells has remained a more laborious and delicate 
process than the selection of aptamers against indi-
vidual compounds. However, the increasing interest in 
this field and the advances in the selection methods are 
reasons to be hopeful that a greater variety of escort 
aptamers and aptamer-based therapeutic and diagnos-
tic agents will appear in the near future. 
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